American Diabetes Association 75th Scientific Sessions
At the American Diabetes Association 75th Scientific Sessions, "top scientists, physicians and other health care professionals from around the world" will "share cutting-edge research, treatment recommendations and advances toward a cure for diabetes."
Q&A With Frank Brosius, MD From the University of Michigan: Treatment for Diabetic Kidney Disease Progressing with More Work to Be Done
Q&A With Frank Brosius, MD From the University of Michigan: How to Diagnose and Educate Others About Diabetic Kidney Disease
Q&A With John Yee From AstraZeneca: Developing New Diabetes Medications and Addressing Potential issues
Q&A with Jaime Davidson from UT Southwestern: New Tool Looks to Bridge the Gap Between Latino Patients with Diabetes and Doctors
Q&A With Jaime Davidson From UT Southwestern: Cultural Details Important in Addressing Diabetes for Latino Community
There are a substantial number of factors physicians must take into consideration before starting a patient with type 2 diabetes mellitus on a particular treatment path. According to results from a recent study, the effectiveness of one of the most popular diabetes medications may be dependent on a patient's race or ethnicity.
With multiple factors hurting patients' chances of reaching type 2 diabetes treatment goals â€“ including a lack of timely follow-up appointments and yo-yo blood glucose (A1C) levels â€“ a respected physician recently advised a major shift in treatment, especially early on in the progressive disease.
Oxidative stress plays an important role in the ability for dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, to effectively ease diabetic nephropathy, according to lead author Takashi Hatanaka of Nagoya University. The study will be presented in a poster session on June 6 at the American Diabetes Association 75th Scientific Sessions in Boston, MA.